공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

뮤코다당증 III형(산필립포 증후군) : 세계 임상시험 리뷰

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 12월 상품 코드 304744
페이지 정보 영문 47 Pages
가격
US $ 2,500 ₩ 2,846,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,692,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,538,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


뮤코다당증 III형(산필립포 증후군) : 세계 임상시험 리뷰 Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017
발행일 : 2017년 12월 페이지 정보 : 영문 47 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

뮤코다당증 III형(MPS III, 산필립포 증후군)에 관련된 임상시험 최신 동향에 대해 분석했으며, 질환 및 치료법 개요, 주요 임상시험 국가, G7 국가 및 E7(신흥 7개국)의 임상시험 건수 및 피험자 채용 상황, 지역·상(相)·단계별 진행 상황, 유망한 스폰서, 각 기업 및 연구기관에서의 연구 진행 상황, 유망한 치료제 비교 등의 정보를 정리하여 전해드립니다.

1. 서론

  • 뮤코다당증 III형(MPS III, 산필립포 증후군)
  • 본 보고서의 개요

2. 지역별 임상시험 상황

3. 각국의 임상시험 건수와 평균 피험자수

  • 유럽 주요 5개국의 임상시험 건수
  • 북미 주요 국가의 임상시험 건수
  • 중남미 주요 5개국의 임상시험 건수

4. G7 국가에서의 임상시험 건수 : 대사성 질환 임상시험 전체 건수 대비 뮤코다당증 III형(MPS III) 임상시험 비율

5. G7 국가에서의 임상시험 건수 : 상(相)별

6. G7 국가에서의 임상시험 건수 : 진척 상황별

7. E7(신흥 7개국)의 임상시험 건수 : 대사성 질환 임상시험 전체 건수 대비 뮤코다당증 III형(MPS III) 임상시험 비율

8. 상(相)별 임상시험 건수

  • 진행중인 임상시험 : 단계별

9. 진척 상황별 임상시험 건수

10. 엔드포인트 달성 상황별 임상시험 건수

11. 미달성 임상시험 건수

12. 일정기간에 채용된 피험자

13. 스폰서 종류별 임상시험 건수

14. 유망한 스폰서

15. 유망한 치료제

16. 임상시험 개요

  • 대표적 기업의 임상시험 개요
    • Shire Plc
    • UniQure NV
    • Lysogene
    • Synageva BioPharma Corp.
    • Cytomedix, Inc.
    • BioMarin Pharmaceutical Inc.
  • 대표적 연구기관 및 병원의 임상시험 개요
    • Academic Medical Center
    • Masonic Cancer Center
    • The University of Manchester
    • The University of Chicago
    • Hospices Civils de Lyon
    • University of Louisville
    • University of Minnesota

17. 대표적 임상시험 5건 개요

부록

도표

LSH 14.06.17

GlobalData's clinical trial report, "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Global Clinical Trials Review, H2, 2017" provides an overview of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials by Phase 19
  • In Progress Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 45

  • Abbreviations 45
  • Definitions 45
  • Research Methodology 46
  • Secondary Research 46
  • About GlobalData 47
  • Contact Us 47
  • Source 47

List of Tables

List of Tables

  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 13
  • Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 14
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 15
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 16
  • Proportion of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 17
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 18
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2017* 19
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 20
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 21
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 22
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 23
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 24
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 25
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 26
  • Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 27
Back to Top
전화 문의
F A Q